Back to top

Innate Pharma completes enrollment in dose escalation of IPH4502 study

Innate Pharma (IPHA) announced the completion of enrollment in the dose escalation of the Phase 1 study of IPH4502, its proprietary Nectin-4 exatec...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Innate Pharma S.A. Sponsored ADR (IPHA)

Innate Pharma SA (IPHYF)